Navigation Links
Approximately One-Third of MS Patients Experiencing Relapses Do Not Adequately Respond to Traditional Corticosteroid Therapy, According to New Data Presented at the 5th Joint Congress of the European and Americas Committees for Treatment and Researc
Date:10/21/2011

AMSTERDAM, Oct. 21, 2011 /PRNewswire/ -- On October 21 at the 5th Joint Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS), results were presented from a survey conducted by NARCOMS which found that about one-third of patients experiencing MS relapses do not adequately respond to corticosteroid treatment.  The survey included over 2,000 patients with MS who had experienced relapses and were treated with either intravenous (IV) or oral corticosteroids.  Corticosteroids are generally considered to be first-line therapy for MS relapses requiring therapy by most neurologists.

Of 1,122 MS patients surveyed who had been treated with IV steroids for their relapses, 31% reported no change or a worsening of relapse symptoms following treatment.  Of 894 MS patients treated with oral steroids for relapses, 39% reported no change or a worsening of symptoms following treatment.

"This NARCOMS survey helps to further our understanding about the experiences and perspectives of patients who are suffering from MS relapses," said Ruth Ann Marrie, MD, PhD, Director of the Multiple Sclerosis Clinic at the Health Sciences Centre, Winnipeg, Manitoba, Canada and NARCOMS representative.  "We hope that such information can be helpful to both physicians and patients in the management of MS."

This survey was one of an ongoing series of patient surveys independently conducted by NARCOMS on a variety of important topics related to MS patient care.  NARCOMS is a non-profit project of the Consortium of Multiple Sclerosis Centers and operates the largest North American MS patient self-report registry, with the ultimate goal of improving research, treatment and education.

"These findings provide a major step forward in the understanding of how MS patients who are suffering relapses view their experience with corticosteroid treatment, which has been the most widely-used first-line relapse treatment for nearly three decades," said Steve Cartt, Executive Vice President and Chief Business Officer of Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR). "The data confirm the need for additional treatment options for MS relapses.  For many of these patients who do not respond adequately to corticosteroid treatment, Acthar can be a viable treatment option."

A brief abstract containing a portion of the NARCOMS survey findings was submitted to ECTRIMS in May 2011 and is currently available for viewing at: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=136977&XNSPRACHE_ID=2&XNKONGRESS_ID=150&XNMASKEN_ID=900

The full poster highlighting key findings from the NARCOMS survey presented at the Congress is expected to be available for viewing on the ECTRIMS website within the next 10 business days at: http://www.ectrims.eu/conferences.htm.  

About H.P. Acthar® Gel

H.P. Acthar® Gel is a natural adrenocorticotropic hormone (ACTH) designed to provide a prolonged release after intramuscular or subcutaneous injection. Acthar is indicated for the treatment of acute exacerbations of multiple sclerosis in adults, and as monotherapy for the treatment of IS in infants and children under 2 years of age. It is also indicated to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus, and for the treatment of several other diseases and disorders. For more information, please visit www.acthar.com.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions. Questcor markets H.P. Acthar® Gel (repository corticotropin injection), which is indicated for the treatment of acute exacerbations of multiple sclerosis in adults, and as monotherapy for the treatment of IS in infants and children under 2 years of age. It is also indicated to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus, and for the treatment of several other diseases and disorders.  The Company also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Finds That Gastric Banding Pays for Itself In Approximately Two Years for Patients With Diabetes and Four Years for Patients Without Diabetes
2. Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
3. PDI Announces Contract Extension With Revenue Value of Approximately $23 Million
4. Unilife COO Makes Open Market Purchase of Approximately $250,000 in Companys Publicly Traded Shares
5. Accuray to Acquire TomoTherapy for Approximately $277 Million in Cash and Stock
6. Court Grants Preliminary Approval to Class Action Settlement that Provides Benefits Of Approximately $20 Million to Healthcare Providers that Purchased a SS1 Before January 1, 2009
7. Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million
8. HA&W Obtains Approximately $2 M in Credits and Cash Grants for Clients Through the Therapeutic Discovery Project Program
9. The Acute Ischemic Stroke Drug Market Will Remain Relatively Flat, Increasing from $460 Million in 2009 to Approximately $610 Million in 2019
10. Consumer Reports Flu Poll: Approximately Three Out of 10 Health Care Workers Living in a Bubble, Not Getting Flu Vaccine
11. The Non-Small-Cell Lung Cancer Drug Market Will Increase From Approximately $4 Billion in 2009 to More Than $6.5 Billion in 2019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017  PMD ... OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... strategic hub service that expedites and streamlines patient and ... Spiro PD 2.0, and wellness management services.  ... medical device used to measure lung function for a ...
Breaking Medicine Technology:
(Date:10/13/2017)... Milwaukee, WI (PRWEB) , ... October 13, 2017 , ... ... movement in medicine known as “patient engagement.” The patient is doing more than filling ... research partners. , “There is an increasing emphasis in health care and research ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical ... the primary prevention of cardiovascular diseases during the 15th Annual Women’s Health ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
Breaking Medicine News(10 mins):